Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop”

The anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) monoclonal antibody ipilimumab was the first in-class immune-checkpoint inhibitor (ICI) approved for the treatment of melanoma patients. Initially approved for metastatic cutaneous melanoma, treatment with ipilimumab subsequently demonstrated to sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Colucci, Maura, D’Alonzo, Vincenzo, Santangelo, Federica, Miracco, Clelia, Valente, Monica, Maio, Michele, Di Giacomo, Anna Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707535/
https://www.ncbi.nlm.nih.gov/pubmed/36457762
http://dx.doi.org/10.2147/OTT.S367389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707535/
https://www.ncbi.nlm.nih.gov/pubmed/36457762
http://dx.doi.org/10.2147/OTT.S367389

Ejemplares similares